Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1.
about
PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical applicationTargeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem CellsHow to take autophagy and endocytosis up a notch.The EF-hand calcium-binding protein tescalcin is a potential oncotarget in colorectal cancerNew frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targetsNuclear factor of activated T-cells 5 increases intestinal goblet cell differentiation through an mTOR/Notch signaling pathway.From genotype to functional phenotype: unraveling the metabolomic features of colorectal cancer.Selective anti-cancer agents as anti-aging drugsPharmacological regulators of autophagy and their link with modulators of lupus diseaseMitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition.Gerosuppression in confluent cells.Up-regulation of lysosomal TRPML1 channels is essential for lysosomal adaptation to nutrient starvation.Interaction of mTOR and Erk1/2 signaling to regulate oligodendrocyte differentiation.DC120, a novel AKT inhibitor, preferentially suppresses nasopharyngeal carcinoma cancer stem-like cells by downregulating Sox2.Targeting tumor-initiating cells: eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction.Koschei the immortal and anti-aging drugsMaturation of embryonic tissues in a lymph node: a new approach for bioengineering complex organs.Trehalose, sucrose and raffinose are novel activators of autophagy in human keratinocytes through an mTOR-independent pathway.mTOR pathway in colorectal cancer: an update.Late-stage inhibition of autophagy enhances calreticulin surface exposure.Targeting mTOR network in colorectal cancer therapyTherapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitationsAutophagy in cancer stem/progenitor cells.Apoptotic and autophagic pathways with relevant small-molecule compounds, in cancer stem cells.Pluripotent Stem Cells to Rebuild a Kidney: The Lymph Node as a Possible Developmental Niche.Therapeutic potential of mTOR inhibitors for targeting cancer stem cells.Regenerating a kidney in a lymph node.Clinical relevance of autophagic therapy in cancer: Investigating the current trends, challenges, and future prospects.All-trans retinoic acid suppresses malignant characteristics of CD133-positive thyroid cancer stem cells and induces apoptosisPrognostic relevance of carbonic anhydrase IX expression is distinct in various subtypes of breast cancer and its silencing suppresses self-renewal capacity of breast cancer cells.The lymph node as a new site for kidney organogenesis.Intra-articular injection of Torin 1 reduces degeneration of articular cartilage in a rabbit osteoarthritis modelTowards Organs on Demand: Breakthroughs and Challenges in Models of Organogenesis.Selective AKT Inhibition by MK-2206 Represses Colorectal Cancer-Initiating Stem Cells.Oncogenic Signalling through Mechanistic Target of Rapamycin (mTOR): A Driver of Metabolic Transformation and Cancer Progression.mTOR signaling promotes stem cell activation via counterbalancing BMP-mediated suppression during hair regeneration.
P2860
Q26801538-5AFADEC3-7248-437D-866F-41E10007C10AQ28078154-0A5C8986-206E-406B-991B-38101A8F8C23Q33594233-17CC3868-02E5-472F-9F1C-957093575662Q33688554-6A51C08E-BCBF-437B-A2BE-D69C689930A0Q33731804-B8F18CDA-4FC2-471E-8829-0260CFE59F70Q34166917-63BAEFBA-6708-4B83-9539-37C91F9C089EQ34347646-30952469-2541-4E45-A01F-4489260F8D05Q34392470-175504ED-FC8A-4CC8-8672-966E9F99F07AQ34402759-42D12079-B1E9-42BC-93B0-4458AE08A594Q34956497-0A8D9B6E-D87D-413A-972E-670A09FF454CQ34982499-7F3CA55A-8834-44D1-8DC1-7020ED64D214Q35212557-C35019DA-A059-4BC5-AE68-B575F22D821CQ35523618-27C6F1C5-AA22-44E3-A587-AF24A0955465Q35740115-645F5562-2C65-456E-8039-0FDDA251C586Q35741514-D9599D41-C491-48C4-AD32-921A37BD44CBQ36292001-55B2C0FA-8E50-4FC6-B018-6399B22E16EAQ36571489-D1F3721B-F803-402A-820E-C979A187CF63Q37027667-89083341-738E-45F0-8DE1-5D2B516B0D18Q37649634-3DE1921A-4114-4B1A-90FA-2AB010C82F2BQ37697081-22D18895-E3BE-416D-9C05-92D3221C92F7Q37708005-C72C4424-171C-490B-AACF-1E1F2EFAB771Q38208069-96F66AA0-40A2-4FB0-827C-74202F77E5B7Q38271354-263AD59A-A8D1-41F5-A715-A8C8D8ACF3E1Q38503469-32BB4959-A1A3-4FDF-A413-11CE5205CD35Q38544732-09B2CDD8-D8AC-4D10-B6C1-4BC275924BD6Q38648562-6C204B9D-E52C-4F3E-B5FE-44B19579165DQ38674374-EC92C95D-A100-4F7D-9D3D-F70CBC9BFCD9Q38689955-6CAB1DE2-9D76-4301-A27E-0CF5DAE6DCCDQ38694704-02434B17-76B0-448D-8C34-226C29C0A712Q38937979-A9079431-1101-4373-B0C4-7B713803AA36Q41487790-A28C4BDB-B07B-457C-A912-1877AE2E9658Q42273139-A45468DD-7AE3-4012-8876-7491B037C52CQ42286926-A89A4478-56BB-41D3-9F1F-78074BA3B3EAQ42381878-E30CF647-788A-4049-86AB-169811712FB0Q47232136-5E9CAB03-4336-487C-A4FA-8D540264B8F3Q51015837-CEACF41F-2C6A-4CFC-BA6A-92EBF028D0EB
P2860
Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1.
@en
Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1.
@nl
type
label
Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1.
@en
Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1.
@nl
prefLabel
Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1.
@en
Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1.
@nl
P2860
P356
P1433
P1476
Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1.
@en
P2093
Eric Lagasse
P2860
P304
P356
10.18632/ONCOTARGET.1310
P407
P577
2013-11-01T00:00:00Z